Study guide
8.3 Types & Characteristics of Cancer: Benign vs. Malignant, Tumor Families, Spread & Precursors
NCRA Oncology Data Specialist ODS-C
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: The ODS-C Exam, the Oncology Data Specialist Profession & Standard Setters
1.1 ODS Exam Structure, Timing, Scoring & 2026 Testing Windows 1.2 From CTR to ODS: The Credential, Eligibility Routes & the Registrar's Role 1.3 Standard-Setting Organizations & the Manuals They Publish
2 Chapter 2: Legal Framework, HIPAA & State Reporting Laws
2.1 HIPAA Privacy Rule & the Public Health Reporting Exception 2.2 HIPAA Security Rule, Safeguards & Breach Notification 2.3 State Mandatory Cancer Reporting Laws & Statutory Authority
3 Chapter 3: Confidentiality, Release of Information, Ethics & Credential Maintenance
3.1 Patient Confidentiality Protocols & Data Access Policies 3.2 Handling Subpoenas, Discovery & Registry Immunity Statutes 3.3 NCRA Code of Ethics & ODS Credential Maintenance
4 Chapter 4: Registry Organization, Staffing & Information Systems
4.1 Types of Cancer Registries, Their Functions & Registry Operating Protocols 4.2 Registry Staffing Formulas, Time Studies & Resource Allocation 4.3 Electronic Registry Systems, Security & Disaster Recovery Planning
5 Chapter 5: Cancer Committee, Cancer Conferences & Quality Improvement
5.1 The Cancer Committee: CoC Standards 2.1–2.4, the CLP & Annual Program Activities 5.2 Multidisciplinary Cancer Case Conferences (CoC Standard 2.5) 5.3 Quality Improvement Principles & CoC Chapter 7 (Standards 7.1–7.3)
6 Chapter 6: CoC Accreditation Standards, NCDB & Data Quality
6.1 CoC Accreditation: Standards Structure, Program Categories & Accreditation Awards 6.2 The National Cancer Database (NCDB), RCRS Submission & CoC Quality Measures 6.3 Quality Control Plans & Audit Techniques (CoC Standard 6.1)
7 Chapter 7: Surveillance Programs, NAACCR Standards, Epidemiology & Statistics
7.1 National Cancer Surveillance Programs: SEER & CDC NPCR 7.2 NAACCR Data Exchange Standards, XML Data Specifications & Registry Certification 7.3 Basic Cancer Epidemiology & Descriptive Statistics 7.4 Basic Statistics: Frequency Distributions, Central Tendency, Risk Ratios & Odds Ratios 7.5 Survival Analysis, Life Tables & Presentation of Registry Data
8 Chapter 8: Medical Terminology, Anatomy & Types of Cancer
8.1 Medical Terminology & Standard Abbreviations for Cancer Abstracting 8.2 Human Anatomy & Physiology for Registrars: Tissues, Organ Walls, Subsites & Lymphatic Drainage 8.3 Types & Characteristics of Cancer: Benign vs. Malignant, Tumor Families, Spread & Precursors
9 Chapter 9: Casefinding & Reportability
9.1 Principles of Casefinding & Facility Reference Dates 9.2 Casefinding Sources: Pathology, Cytology, Disease Index & Logs 9.3 Reportability: What CoC, SEER and NPCR Require, Including Non-Malignant CNS Tumors 9.4 Ambiguous Terminology: Reportable Terms, Cytology, Discrepancies & "References of Last Resort"
10 Chapter 10: Diagnostic Procedures, Pathology Reporting, Lab Methods & Prognostic Indicators
10.1 Diagnostic & Staging Procedures: Imaging, Endoscopy, Biopsy & How They Are Coded 10.2 Pathology Reporting, CAP Cancer Protocols & Electronic Pathology (CoC Standard 5.1) 10.3 Specialty Laboratory Testing Methods: IHC, FISH, PCR/RT-PCR, NGS, Flow Cytometry & Cytogenetics 10.4 Prognostic Indicators & Site-Specific Data Items (SSDIs): HPV, KRAS, HER2 and More
11 Chapter 11: Class of Case, Key Dates & Case Identifiers
11.1 Class of Case, Date of First Contact, Date of Diagnosis & Accession/Sequence Numbers 11.2 Analytic Classes of Case (00, 10–14, 20–22): Definitions & Decision Rules 11.3 Nonanalytic Classes of Case (30–49, 99) & Why Central Registries Need Them
12 Chapter 12: Follow-Up, Vital Status & Recurrence
12.1 Follow-Up Purpose, Active & Passive Methods, and Follow-Up Source Codes 12.2 CoC Standard 6.5 Follow-Up Rates: Windows, Exclusions & Calculations 12.3 Vital Status, Date of Last Contact, Cancer Status & Death Clearance 12.4 Recurrence: Type of First Recurrence [1880], Date of First Recurrence [1860] & Recurrence vs. New Primary
13 Chapter 13: Abstracting, ICD-O-3.2 Site & Histology Coding, and Grade
13.1 The Abstracting Process: Workflow, Source Documents, Timeliness & Text Documentation 13.2 ICD-O-3.2 Topography, Primary Site Rules & Laterality 13.3 ICD-O-3.2 Morphology: Histology, Behavior & the Solid Tumor Histology Rules 13.4 Grade: The Four Time-Specific Grade Items & Site-Specific Grade Tables
14 Chapter 14: Solid Tumor Rules & Hematopoietic Coding Rules
14.1 Solid Tumor Rules: Purpose, Site Groups, Navigation & Timing Principles 14.2 Solid Tumor Rules for Breast, Colon/Rectum & Lung: The Multiple Primary Rules in Order 14.3 Solid Tumor Rules for Head & Neck, Kidney, Urinary, CNS, Melanoma & Other Sites 14.4 Hematopoietic & Lymphoid Neoplasms: Heme Manual, Heme DB, Multiple Primary & Primary Site Rules
15 Chapter 15: Staging: AJCC TNM (8th Edition & Version 9 Lung) and Summary Stage 2018
15.1 AJCC TNM Principles: Categories, Prefixes, Suffixes, General Rules & Registry Items 15.2 AJCC Time Frames: Clinical, Pathological, Post-Therapy (yc, yp), Recurrence & Autopsy 15.3 Breast Staging (AJCC 8th Edition, Part XI): T, N, M, Anatomic & Prognostic Stage Groups 15.4 Lung Staging (AJCC Version 9, 2025+): T, N2a/N2b, M1c1/M1c2 & New Stage Groups 15.5 Male Genital & Urinary Tract Staging (AJCC 8th Parts XIII–XIV): Prostate, Testis, Kidney, Bladder, Renal Pelvis & Ureter 15.6 SEER Summary Stage 2018: Codes, Timing, General Rules & Site Examples
16 Chapter 16: First-Course Treatment Coding (STORE 2025) & EDITS
16.1 Treatment Types, First Course of Treatment & Evidence-Based Guidelines (NCCN) 16.2 Surgery Coding: Rx Summ–Surg 2023 [1291], Lymph Node Surgery [1292], Other Site [1294], Margins & Reason for No Surgery 16.3 Radiation, Systemic, Transplant, Other & Palliative Treatment Coding (STORE 2025) 16.4 NAACCR EDITS, Over-ride Flags & Data Validation
8.3 Types & Characteristics of Cancer: Benign vs. Malignant, Tumor Families, Spread & Precursors
Key Takeaways Explain This Topic AI
Malignant neoplasms invade surrounding tissue and can metastasize; benign neoplasms grow locally, are usually encapsulated and well differentiated, and do not metastasize.
Registries code behavior as /0 benign, /1 uncertain or borderline, /2 in situ, or /3 malignant; /6 (metastatic site) and /9 (uncertain whether primary or metastatic) are not used in registry abstracts.
Cancer spreads by direct extension to adjacent tissue, through lymphatics to lymph nodes, through the bloodstream to distant organs, and by seeding across body cavities such as the peritoneum.
Oncogenes (such as KRAS and ERBB2/HER2) drive growth when activated, while tumor suppressor genes (such as TP53, RB1, APC and BRCA1/2) promote cancer when inactivated.
Precursor lesions such as colon adenomas, Barrett esophagus and MGUS are not reportable on their own, but they explain multiple primary and histology rules.
Last updated: September 2026
Why this topic matters
"Types and characteristics of cancer" is a Domain 3 knowledge area. It lets a registrar recognize a malignancy described in unfamiliar words, choose the right coding manual (solid tumor or hematopoietic), and understand why the staging and multiple primary rules work the way they do.
Benign versus malignant
- Characteristic Benign neoplasm Malignant neoplasm
- Growth Usually slow and expansive Often rapid; invasive and infiltrating
- Borders Usually well circumscribed or encapsulated Poorly defined; invades neighboring tissue
Differentiation Well differentiated; resembles the tissue of origin Ranges from well differentiated to anaplastic
- Invasion of the basement membrane No Yes (in situ lesions have malignant cells that have not yet invaded)
- Metastasis Never Possible, and the defining feature of malignancy
- Recurrence after excision Uncommon Common
Behavior codes (the fifth digit of the ICD-O morphology code) capture this spectrum: /0 benign, /1 uncertain whether benign or malignant (borderline or low malignant potential), /2 in situ (intraepithelial, noninvasive), and /3 malignant, primary site. ICD-O also has /6 (metastatic site) and /9 (uncertain whether primary or metastatic), but registries do not use them . A primary tumor is always coded /3 even when the only biopsy came from a metastasis.
Families of cancer by cell of origin
Family Origin Examples
Carcinoma Epithelium; about 80–90% of cancers Squamous cell carcinoma, adenocarcinoma, urothelial carcinoma, neuroendocrine carcinoma
Sarcoma Mesenchymal (connective) tissue Osteosarcoma, leiomyosarcoma, liposarcoma, GIST
Lymphoma Lymphocytes, usually in lymph nodes or lymphoid tissue Hodgkin lymphoma, diffuse large B-cell lymphoma, follicular lymphoma
- Leukemia Blood-forming cells in the bone marrow AML, ALL, CML, CLL
- Plasma cell neoplasms Plasma cells Plasma cell myeloma, plasmacytoma
- Melanoma Melanocytes Cutaneous, mucosal and uveal melanoma
- Germ cell tumors Germ cells Seminoma, embryonal carcinoma, yolk sac tumor, choriocarcinoma, teratoma
- CNS tumors Glial and neuronal cells, meninges Glioblastoma, astrocytoma, oligodendroglioma, meningioma
Embryonal tumors (-blastomas) Immature precursor cells, mostly in children Neuroblastoma, nephroblastoma (Wilms), retinoblastoma, medulloblastoma
Mixed tumors More than one cell line Adenosquamous carcinoma, carcinosarcoma, mixed germ cell tumor
Hematopoietic and lymphoid neoplasms (ICD-O codes 9590–9993) follow the Hematopoietic Manual and Database . All other malignancies follow the Solid Tumor Rules .
How cancer develops
Genetic damage accumulates in a cell line: from inherited (germline) mutations and from acquired (somatic) damage caused by carcinogens or random copying errors.
Oncogenes are normal growth-promoting genes (proto-oncogenes) that become overactive through mutation, amplification or translocation. Examples are KRAS and NRAS (colorectal and lung cancer), ERBB2 (HER2) amplification (breast and gastric cancer), BCR::ABL1 (CML), and EGFR and ALK rearrangements (lung cancer).
Tumor suppressor genes normally restrain growth or repair DNA. Cancer develops when both copies are lost. Examples are TP53 , RB1 (retinoblastoma), APC (familial adenomatous polyposis) and BRCA1/BRCA2 (hereditary breast and ovarian cancer).
DNA mismatch repair genes (MLH1, MSH2, MSH6, PMS2): their loss causes microsatellite instability (MSI-H/dMMR) . When inherited, this is Lynch syndrome (colorectal, endometrial and other cancers).
Carcinogenesis is often described in stages: initiation (DNA damage), promotion (clonal expansion) and progression (invasion and metastasis).
Major risk factors
Tobacco, alcohol, obesity and inactivity, ultraviolet radiation, and ionizing radiation.
Infections: HPV (cervical, oropharyngeal and anal cancer), hepatitis B and C (liver), Helicobacter pylori (stomach cancer and gastric MALT lymphoma), EBV (nasopharyngeal carcinoma and some lymphomas), HHV-8 (Kaposi sarcoma).
Occupational and environmental exposures: asbestos (mesothelioma), benzene (leukemia), aromatic amines (bladder cancer).
Inherited syndromes: Lynch, HBOC (BRCA1/2), FAP, Li-Fraumeni (TP53), von Hippel-Lindau, and the multiple endocrine neoplasias.
How cancer spreads
Route Mechanism Registry relevance
Direct extension Continuous growth into adjacent tissue or organs Raises the T category; Summary Stage "regional by direct extension"
Lymphatic Tumor cells travel to regional, then distant, lymph nodes N category; distant nodes are M1
Hematogenous (bloodstream) Tumor cells enter blood vessels and seed distant organs M1. GI cancers commonly spread to the liver through the portal vein; breast, lung and prostate cancers often go to bone; lung and breast cancers to the brain
Implantation (seeding) Tumor cells shed across body cavities or along a biopsy or surgical tract Peritoneal carcinomatosis in ovarian and gastric cancer; malignant effusions
Tumor deposits , satellite nodules and in-transit metastases (in melanoma) are discontinuous spread through lymphatics. Staging systems assign them specifically; for example, melanoma satellites are counted as nodal disease in Summary Stage 2018.
Precursor and borderline lesions
Lesion Meaning Registry status (CoC)
Colon adenoma with high-grade dysplasia (8210/2, 8211/2, 8261/2, 8263/2) Precursor to adenocarcinoma Not required by CoC for diagnoses on or after January 1, 2022; check state rules
- Barrett esophagus Metaplasia that predisposes to adenocarcinoma Not reportable
- CIN III / cervical carcinoma in situ, PIN III Intraepithelial neoplasia Not reportable
VIN III, VAIN III, AIN III Intraepithelial neoplasia of the vulva, vagina and anus Not required by CoC, but reportable to SEER and NPCR central registries
- LCIS (8520/2) Lobular carcinoma in situ of the breast Not required by CoC; required by SEER and NPCR
- MGUS Monoclonal gammopathy that precedes myeloma Not reportable
- Borderline ovarian tumor (/1) Low malignant potential Not reportable
- (Reportability details are in Section 9.3.)
- Grade versus stage
Grade describes how abnormal the cells look under the microscope, or their biology (for example, the Gleason Grade Group). Stage describes how far the tumor has spread in the body. A small tumor can be high grade, and a large tumor can be low grade. The two are recorded separately: grade in the Grade Clinical and Grade Pathological items, stage in AJCC and Summary Stage.